A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

NCT02040779 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

273

Enrollment

INDUSTRY

Sponsor class

Conditions

Persistent Asthma

Interventions

DRUG: Beclomethasone dipropionate breath-actuated inhaler
DRUG: Placebo breath-actuated inhaler
DRUG: albuterol/salbutamol

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.